Abstract：
An early, extensive, accurate, and cost-effective clinical diagnosis of neurocognitive disorders will have advantages for older people and their families, but also for the health and care systems sustainability and performance. BRAINCODE is a technology that assesses cognitive impairment in older people, differentiating normal from pathologic brain condition, based in an EEG biomarkers evaluation. This paper will address BRAINCODE\'s pilot design, which intends to validate its efficacy, to provide guidelines for future studies and to allow its integration on the SHAPES platform. It is expected that BRAINCODE confirms a regular clinical diagnosis and neuropsychologic tests to discriminate \'normal\' from pathologic cognitive decline and differentiates mild cognitive impairment from dementia in older adults with/without subjective cognitive complains.
摘要：
很早,广泛的，准确,并且具有成本效益的神经认知障碍的临床诊断将对老年人及其家庭具有优势，但也为医疗保健系统的可持续性和性能。BRAINCODE是一种评估老年人认知障碍的技术，区分正常和病理性大脑状况，基于脑电图生物标志物评估。本文将讨论BRAINCODE的试点设计，旨在验证其功效，为未来的研究提供指导，并允许其在SHAPES平台上的整合。预计BRAINCODE会定期进行临床诊断和神经心理测试，以区分“正常”和病理性认知衰退，并区分有/没有主观认知抱怨的老年人的轻度认知损害和痴呆。
